First-line pembrolizumab and trastuzumab in HER2-positive esophagogastric cancer

BACKGROUND: Adding trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety and efficacy of pembrolizumab in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic esophagogastric (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Janjigian, Yelena Y., Maron, Steven B., Chatila, Walid K., Millang, Brittanie, Chavan, Shweta S., Alterman, Carly, Chou, Joanne F., Simmons, Marc, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y., Zervoudakis, Alice, Won, Elizabeth S., Kelsen, David P., Ilson, David H., Nagy, Rebecca J., Lanman, Richard B., Ptashkin, Ryan N., Donoghue, Mark T.A., Capanu, Marinela, Taylor, Barry S., Solit, David B., Schultz, Nikolaus, Hechtman, Jaclyn F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8229851/
https://ncbi.nlm.nih.gov/pubmed/32437664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30169-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados